Mine Moosakhanian
Primary Care · Simi Valley, CANPI 1881310761
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,496 and has fallen 59.6% since, to $605 in 2025. Among primary care clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $22.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$796
- Novo Nordisk$730
- Lilly USA, LLC$596
- AstraZeneca$384
- Boehringer Ingelheim$223
- Bayer$134
- plus $744 from 14 others
What the payments were for
- Food & beverage$3,607100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $796 |
| Novo Nordisk | 35 | $730 |
| Lilly USA, LLC | 22 | $596 |
| AstraZeneca | 19 | $384 |
| Boehringer Ingelheim | 10 | $223 |
| Bayer | 7 | $134 |
| Idorsia Pharmaceuticals US Inc | 6 | $116 |
| Amgen | 4 | $104 |
| Johnson & Johnson | 4 | $93 |
| Merck | 3 | $78 |
| Pfizer | 4 | $75 |
| Medtronic | 2 | $63 |
| Novartis | 2 | $53 |
| GSK | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Dexcom, Inc. | 1 | $21 |
| Exact Sciences | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Almatica Pharma LLC | 1 | $18 |
| Phadia US Inc. | 1 | $17 |
How this compares
$3,607 in reported general payments places this provider in the 90th percentile of 706 primary care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 27 | $32,520 |
| OzempicSemaglutide | 30 | $27,778 |
| JardianceEmpagliflozin | 13 | $21,888 |
| XareltoRivaroxaban | 21 | $21,872 |
| WegovySemaglutide | 12 | $16,424 |
| JanuviaSitagliptin Phosphate | 11 | $14,985 |
| EliquisApixaban | 16 | $11,307 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $11,274 |
| FarxigaDapagliflozin Propanediol | 11 | $9,018 |
| Rivastigmine | 11 | $3,397 |
| Levothyroxine Sodium | 124 | $1,705 |
| Atorvastatin Calcium | 156 | $1,346 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 73 | $1,079 |
| SynthroidLevothyroxine Sodium | 13 | $815 |
| Losartan Potassium | 108 | $719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $730 | $44,20242 claims |
| Lilly USA, LLCMounjaro | $596 | $32,52027 claims |
| Boehringer IngelheimJardiance | $223 | $21,88813 claims |
| Johnson & JohnsonXarelto | $93 | $21,87221 claims |
| MerckJanuvia | $78 | $14,98511 claims |
| PfizerEliquis | $75 | $11,30716 claims |
| GSKTrelegy Ellipta | $40 | $11,27414 claims |
| AstraZenecaFarxiga | $384 | $9,01811 claims |
| AbbVieSynthroid | $796 | $81513 claims |
| Almatica Pharma LLCSertraline Hcl | $18 | $26434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 706 primary care providers in California.
Other primary care in Simi Valley
- Leslie FletcherTorrance$1.8M
- Hamideh PourzandLos Angeles$103K
- Veronica RamirezSacramento$83K
- Tyson FieldstedBakersfield$65K
- Kathryn CooperSan Diego$31K
- Shalaine Corbillala Mesa$22K
- Paula StoddardHanford$22K
- Ashley LoweSan Diego$19K
- Vanessa LeeLong Beach$16K
- Lynda TranHuntington Beach$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.